Agilon Health, Inc. (NYSE:AGL) reported a recent transaction involving Chief Medical & Quality Officer Kornitzer Benjamin, who acquired shares in the company. The transaction, which took place on March 14, 2024, involved the purchase of 5,434 shares of common stock. However, the transaction resulted in a total value of $0, indicating that the shares may have been acquired at no cost to the officer.
The same filing also reported a transaction under code "F," where 1,883 shares of common stock were withheld by Agilon Health to satisfy tax withholding obligations related to the vesting of performance-based restricted stock units (PSUs). This transaction, which is not considered a sale, had a total value of $9,848, based on a price of $5.23 per share.
The PSUs vested based on the company's achievement of predetermined revenue and Adjusted EBITDA goals over a three-year period, with a total attainment of 100%. The vested PSUs were settled in shares of common stock on their scheduled vesting date.
Following these transactions, Kornitzer's direct ownership in Agilon Health stands at 62,058 shares, which includes restricted stock units. The company's stock, which trades under the ticker AGL, may see investor interest following these insider transactions, as they often provide insights into executives' expectations and confidence in the company's performance.
InvestingPro Insights
Agilon Health, Inc. (NYSE:AGL) has caught the attention of the market not only due to insider transactions but also because of its interesting financial metrics and strategic moves. The company's management has been assertively repurchasing shares, a sign that could be interpreted as confidence in the company's future prospects. Moreover, Agilon Health maintains a stronger liquidity position by holding more cash than debt on its balance sheet, which provides a cushion against market volatility and unforeseen expenses.
On the financial front, Agilon's market capitalization stands at approximately 2.21 billion USD. Despite a challenging profitability outlook, with analysts not expecting the company to be profitable this year, Agilon Health has demonstrated significant revenue growth of 80.74% over the last twelve months as of Q1 2023. However, this growth comes with the caveat of weak gross profit margins, which were reported at 1.61% for the same period.
Investors should note that the company's stock has been trading near its 52-week low, and the price has undergone a considerable decline over the past year. The price, as of the previous close, was 5.32 USD. These price movements are critical to consider when assessing the company's stock for potential investment.
For those interested in a deeper dive into Agilon Health's financial health and stock performance, there are additional InvestingPro Tips available that could provide further insights. For instance, Agilon's stock has experienced significant price drops over the last three and six months, which might suggest a potential buying opportunity for value investors or could serve as a cautionary signal for those concerned about short-term volatility. In total, there are 12 additional InvestingPro Tips accessible for Agilon Health, offering a comprehensive analysis for prospective investors.
For a detailed analysis and more tips, consider exploring InvestingPro for Agilon Health. Remember to use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a wealth of information and insights to inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.